SSTR2 Protein-VLP (AA 1-369)
Aperçu rapide pour SSTR2 Protein-VLP (AA 1-369) (ABIN7448172)
Antigène
Voir toutes SSTR2 ProtéinesType de proteíne
Activité biologique
Origine
Source
Application
Pureté
-
-
Attributs du protein
- AA 1-369
-
Fonction
- Human SSTR2 Protein-VLP
-
Séquence
- Met1-Ile369
-
Attributs du produit
- Recombinant Human SSTR2 Protein-VLP is expressed from HEK293.It contains Met1-Ile369.
-
Stérilité
- 0.22 μm filtered
-
niveau d'endotoxine
- Less than 1EU per μg by the LAL method.
-
Biological Activity Comment
- Immobilized Human SSTR2 VLP at 5μg/ml on the plate (100μl/Well). Dose response curve for Anti-SSTR2 Antibody, hFc Tag with the EC50 of 32.8ng/ml determined by ELISA.
-
-
Vous souhaitez d'autres options pour ce Protein ?
!Découvrez nos protéines personnalisées prédéfinies et nos services de protéines sur mesure !ProduitSystème d'expressionConjuguéOriginPrix à partir deSystème d'expression HEK-293 CellsConjugué His tagOrigin HumanPrix à partir de 16.256,82 €Système d'expression Cell-free protein synthesis (CFPS)Conjugué Strep TagOrigin HumanPrix à partir de 18.117,43 €Votre projet nécessite-t-il une personnalisation supplémentaire ? Contactez-nous et découvrez nos solutions protéiques sur mesure
-
-
-
Indications d'application
-
- Antibody Discovery: Immunization, Screening, Functional Characterization
- Affinity determination: ELISA, SPR
- In vivo pharmacokinetic analysis
- CMC method development
- CAR-T Positive Rate Detection
- Blood sample determination: ELISA
-
Commentaires
-
Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.
Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.
Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
-
Supplied as 0.22μm filtered solution in PBS, 300 mM L-Arginine ( pH 7.4).
Notice: If you need it for immunization, Do Not use any adjuvant. -
Stock
- -80 °C
-
Stockage commentaire
- Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
-
Date de péremption
- 12 months
-
-
- SSTR2 (Somatostatin Receptor 2 (SSTR2))
-
Autre désignation
- SSTR2
-
Sujet
- Somatostatin receptor (SSTR) 2, widely expressed in meningioma, is a G-protein-coupled receptor and can be activated by somatostatin or its synthetic analogs. SSTR2 is therefore extensively studied as a marker and target for the diagnosis and treatment of meningioma.
-
Poids moléculaire
- 42.7 kDa.
-
UniProt
- P30874-1
Antigène
-